Identifying Cost-Effective Predictive Rules of Amyloid-beta Level by Integrating Neuropsychological Tests and Plasma-Based Markers

摘要

Background: Detecting participants who are positive for amyloid-beta (A beta) pathology is germane in designing prevention trials by enriching for those cases that are more likely to be amyloid positive. Existing brain amyloid measurement techniques, such as the Pittsburgh Compound B-positron emission tomography and cerebrospinal fluid, are not reasonable first-line approaches limited by either feasibility or cost.